E3 ligase SOCS3 regulates NOD2 expression by ubiquitin proteasome system in lung cancer progression
Cellular Oncology · 2024
DOI: 10.1007/s13402-023-00896-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Oncology, 2024. Verfasst von In-Ho Jeong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea. Hauptthemen laut MEDLINE: Suppressor of Cytokine Signaling 3 Protein, Lung Neoplasms, Cell Proliferation, Proteasome Endopeptidase Complex. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Research Foundation of Korea grant funded by the Korean government.
Abstract (Originalsprache)
PURPOSE: Despite lung cancer is one of the leading causes of cancer-related deaths, it remains hard to discover effective diagnostic and therapeutic approaches. Moreover, the five-year survival rate is relatively lower than other tumors. So urgent needs for finding a new theranostic target to treat lung cancer effectively. This study aims to present SOCS3 and NOD2 proteins as novel targets for diagnosis and therapy. METHODS: We first confirmed SOCS3 expression level in patients' tissues. Then, we applied knockdown and overexpression of SOCS3 on lung cancer cell lines and performed proliferation, migration, and invasion assay. After that, we found NOD2 is a target of SOCS3 and introduced overexpression of NOD2 to A549 for verifying reduced tumorigenicity of lung cancer cells. RESULTS: We identified protein expression level of SOCS3 was frequently higher in tumor tissues than adjacent normal tissues. Truly, overexpression of SOCS3 promoted proliferation, migration, and invasion capacity of lung cancer cells. We found that SOCS3 interacts with NOD2 and SOCS3 ubiquitinates NOD2 directly. Furthermore, lung cancer tissues with higher SOCS3 expression showed lower NOD2 expression. We confirmed overexpression of NOD2 leads to suppressed tumorigenicity of lung cancer cells, and these effects occurred through MAPK pathway. CONCLUSION: Collectively, our work reveals novel roles of SOCS3 in lung tumorigenesis and proposes SOCS3 as a promising biomarker candidate for therapeutic and diagnostic target for lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea.
- Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea.
- Department of Microbiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea.
- Department of Physiology, College of Medicine, Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, 21999, Korea.
- Division of Rheumatology, Department of Medicine, Seoul St. Mary's Hospital, Catholic University, Seoul, 06591, Korea. jylee217@catholic.ac.kr.
- Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea. geundy@hanmail.net.
Förderung
- National Research Foundation of Korea grant funded by the Korean government
Zitieren
APA
Jeong, I. H., Yun, J. K., Jin, J. O., Hong, J. H., Lee, J. Y., Lee, G. D., & Lee, P. C. (2024). E3 ligase SOCS3 regulates NOD2 expression by ubiquitin proteasome system in lung cancer progression. Cellular Oncology. https://doi.org/10.1007/s13402-023-00896-5
Vancouver
Jeong IH, Yun JK, Jin JO, Hong JH, Lee JY, Lee GD, et al. E3 ligase SOCS3 regulates NOD2 expression by ubiquitin proteasome system in lung cancer progression. Cellular Oncology. 2024. doi:10.1007/s13402-023-00896-5
BibTeX
@article{Jeong2024,
author = {Jeong, In-Ho and Yun, Jae Kwang and Jin, Jun-O and Hong, Jeong Hee and Lee, Ji Yeon and Lee, Geun Dong and Lee, Peter Chang-Whan},
title = {E3 ligase SOCS3 regulates NOD2 expression by ubiquitin proteasome system in lung cancer progression},
journal = {Cellular Oncology},
year = {2024},
doi = {10.1007/s13402-023-00896-5}
}
EUVIMED